Innovative Approach to Combat Leukemia by Disrupting Cancer Cell Signaling
Scientists at MUSC have developed a novel immunotherapy targeting a signaling loop in leukemia cells, promising improved treatments for AML and beyond. This approach disrupts the cancer's protective environment and boosts immune response, showing potential for safer, more effective therapies.
Researchers at the Medical University of South Carolina's Hollings Cancer Center have made a breakthrough in leukemia treatment by identifying and targeting a critical signaling loop responsible for the growth and survival of leukemia cells. Published in Nature Communications, this study unveils how disrupting the loop between the protein IL-33 and its receptor IL1RL1 can weaken the protective environment around leukemia stem cells, making them more vulnerable to treatment.
Leukemia, particularly acute myeloid leukemia (AML), is notorious for its aggressive nature and tendency to relapse even after standard therapies. A key challenge is the disease's ability to hide in the bone marrow through leukemia stem cells that evade chemotherapy. These cells, supported by a feedback loop involving IL-33 and IL1RL1, promote tumor growth and create an immune-suppressive microenvironment that shields the cancer.
To overcome this, the research team developed a novel bispecific antibody immunotherapy. This innovative treatment simultaneously blocks the IL-33/IL1RL1 signaling and activates T-cells like CD8+ to attack the leukemia cells directly. In preclinical models, this dual-action antibody effectively destroyed leukemia cells, dismantled their protective immune barriers, and slowed disease progression. Remarkably, the therapy led to improved survival rates without significant side effects.
Dr. Sophie Paczesny, the lead researcher and co-chair of the Cancer Biology and Immunology Research Program, emphasized the potential of this approach. She highlighted that IL1RL1 is also expressed in other cancers, including colorectal, lung, ovarian, and brain tumors, suggesting that this strategy could have broad applications. The treatment’s reduced toxicity and easier manufacturing process compared to current therapies could make it a safer, more accessible option for patients.
This research marks an important step toward targeted immunotherapy that not only kills cancer cells but also dismantles the immune defenses they exploit. While further clinical trials are necessary, such treatments could revolutionize care for AML and potentially other cancers with similar microenvironmental features, offering new hope for cases resistant to existing therapies.
For more details, visit ScienceX.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Using Mouse Bait with Tick Pesticide Significantly Reduces Infected Tick Populations in Field Trials
Field studies show that using mouse bait with tick pesticide can lower infected tick populations by 39%, offering a promising strategy to limit Lyme disease transmission in high-risk areas.
Large Study Finds Statins Significantly Reduce Death Risk in Critical Sepsis Patients
A large cohort study reveals that statin therapy may lower the risk of death by 39% in critically ill sepsis patients, highlighting a promising adjunct treatment option. Learn more about the potential benefits of statins in sepsis management.
Investigating the Impact of Bee Venom on Blood Vessel Functionality
Research reveals that bee venom affects blood vessel function, highlighting its toxic effects and potential for vascular disease therapies. Explore the latest findings from UAB scientists.
Understanding How Hippocampal Place Cells and Synaptic Plasticity Drive Memory Formation
Recent studies reveal how hippocampal place cells and synaptic plasticity underpin the brain's ability to gradually acquire and retain memories without overwriting them, offering new insights into neural learning mechanisms.